Generic Relyvrio Availability
Last updated on Oct 9, 2024.
Relyvrio is a brand name of sodium phenylbutyrate/taurursodiol, approved by the FDA in the following formulation(s):
RELYVRIO (sodium phenylbutyrate; taurursodiol - for suspension;oral)
-
Manufacturer: AMYLYX
Approval date: September 29, 2022
Strength(s): 3GM/PACKET;1GM/PACKET [RLD]
Has a generic version of Relyvrio been approved?
No. There is currently no therapeutically equivalent version of Relyvrio available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Relyvrio. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions for improving cell viability and methods of use thereof
Patent 10,251,896
Issued: April 9, 2019
Inventor(s): Cohen Joshua & Klee Justin
Assignee(s): Amylyx Pharmaceuticals Inc.This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress.
Patent expiration dates:
- December 24, 2033✓
- December 24, 2033
-
Compositions for improving cell viability and methods of use thereof
Patent 10,857,162
Issued: December 8, 2020
Inventor(s): Cohen Joshua & Klee Justin
Assignee(s): Amylyx Pharmaceuticals Inc.This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress.
Patent expiration dates:
- December 24, 2033✓
- December 24, 2033
-
Compositions for improving cell viability and methods of use thereof
Patent 11,071,742
Issued: July 27, 2021
Inventor(s): Cohen Joshua & Klee Justin
Assignee(s): Amylyx Pharmaceuticals Inc.This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress.
Patent expiration dates:
- December 24, 2033✓
- December 24, 2033
-
Patent 11,583,542
Patent expiration dates:
- July 27, 2040✓
- July 27, 2040
-
Compositions for improving cell viability and methods of use thereof
Patent 9,872,865
Issued: January 23, 2018
Inventor(s): Cohen Joshua & Klee Justin
Assignee(s): Amylyx Pharmaceuticals Inc.This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress.
Patent expiration dates:
- December 24, 2033✓
- December 24, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- September 29, 2027 - NEW CHEMICAL ENTITY
- September 29, 2029 - TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS
More about Relyvrio (sodium phenylbutyrate / taurursodiol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous central nervous system agents
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
